BioSpace News Archive

Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24th Annual Meeting of the American Society of Gene and Cell Therapy

IMV Inc., a clinical stage immuno-oncology company announced that IMV’s executive management team will be participating in two upcoming investor conferences

Evaxion Biotech A/S, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced the first quarter 2021 financial results and provided an operational update.

Atreca, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, announced financial results for the first quarter ended March 31, 2021, and provided an overview of recent developments.

Nortech Systems Incorporated (Nasdaq: NSYS) (the “Company”), a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products serving the medical, aerospace & defense and industrial markets, reported net sales of $22.1 million for the quarter ended March 31, 2021, a decline of 19.6% compared to $27.4 for the first quarter of 2020

Diaceutics PLC (AIM:DXRX) today announces a new partnership with LGC SeraCare (“SeraCare”), the US-based manufacturer of diagnostic test reference standard controls.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the podium presentation of four clinical studies of NPS technology at the American Society for Laser Medicine and Surgery (ASLMS) Virtual Annual Meeting taking place on May 15-16, 2021.

Seattle Cancer Care Alliance (SCCA), the only National Comprehensive Cancer Network designated cancer center in Washington State, today announced that it is an authorized treatment center for the new B-cell maturation antigen (BCMA) targeted chimeric antigen receptor (CAR) T-cell therapy, idecabtagene vicleucel, also known as ide-cel.

First Nation Group launches new division, First Nation Pharmaceuticals, offering generic pharmaceutical distribution and supply chain management

United Spinal Association has launched a membership drive in celebration of its 75 years of service to the spinal cord injury and disorder community, offering its members a chance to win a variety of prizes donated by companies committed to “Building an Inclusive World” for people with disabilities.